在侵袭性临床前小鼠肿瘤模型中靶向成纤维细胞活化蛋白-α的高效α与β放射性核素治疗
在表达人成纤维细胞活化蛋白-α(hFAP)的肺癌免疫健全小鼠模型中,研究靶向FAP的单域抗体4AH29分别标记225Ac或131I后的体内分布与疗效,并探索与PD-L1免疫检查点阻断联合。结果显示两种示踪剂均有高且持久的肿瘤摄取,低剂量和高剂量治疗均较溶媒显著延长生存;225Ac标记治疗上调肿瘤PD-L1表达,与PD-L1阻断联合显示治疗协同作用。
要点
- 131I标记的GMIB-4AH29注射后1小时肿瘤摄取为3.5±0.5% IA/g,24小时降至0.9±0.1% IA/g。
- 225Ac标记的DOTA-4AH29注射后1小时肿瘤摄取为2.1±0.5% IA/g,24小时为1.7±0.2% IA/g。
- 低剂量和高剂量131I或225Ac标记治疗均较溶媒溶液显著延长生存,高剂量225Ac联合PD-L1阻断显示治疗协同。
核心结论
- 225Ac标记的DOTA-4AH29和131I标记的GMIB-4AH29具有高且持久的肿瘤靶向能力,在荷侵袭性肿瘤小鼠中转化为生存延长。
- PD-L1免疫检查点阻断与225Ac标记的DOTA-4AH29靶向放射性核素治疗联合可增强其治疗疗效。
研究设计与样本
- 在表达人FAP的肺癌免疫健全小鼠模型中研究靶向FAP单域抗体4AH29标记225Ac或131I的靶向放射性核素治疗。
- 通过离体γ计数研究131I标记的GMIB-4AH29和225Ac标记的DOTA-4AH29的体内分布与肿瘤摄取。
- 在免疫健全小鼠模型中评估131I标记的GMIB-4AH29和225Ac标记的DOTA-4AH29的治疗疗效。
- 对225Ac标记的DOTA-4AH29治疗小鼠的肿瘤进行流式细胞术分析。
- 重复225Ac标记的DOTA-4AH29治疗并与PD-L1免疫检查点阻断联合。
主要发现
- 131I标记的GMIB-4AH29注射后1小时肿瘤摄取为3.5±0.5% IA/g,24小时后降至0.9±0.1% IA/g。
- 225Ac标记的DOTA-4AH29注射后1小时肿瘤摄取为2.1±0.5% IA/g,24小时后为1.7±0.2% IA/g,下降较缓。
- 与溶媒溶液相比,低剂量和高剂量131I标记的GMIB-4AH29或225Ac标记的DOTA-4AH29治疗后生存显著改善。
- 与溶媒溶液相比,225Ac标记的DOTA-4AH29治疗小鼠肿瘤中PD-L1表达显著更高。
- 高剂量225Ac标记的DOTA-4AH29与PD-L1免疫检查点阻断联合显示治疗协同作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting sdAbs (4AH29) labelled with 225Ac or 131I in immunocompetent mice in a human FAP (hFAP) expressing lung cancer mouse model. We further explored the combination of TRT with programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (ICB). METHODS: We studied the biodistribution and tumour uptake of [131I]I-GMIB-4AH29 and [225Ac]Ac-DOTA-4AH29 by ex vivo γ-counting. Therapeutic efficacy of [131I]I-GMIB-4AH29 and [225Ac]Ac-DOTA-4AH29 was evaluated in an immunocompetent mouse model. Flow cytometry analysis of tumours from [225Ac]Ac-DOTA-4AH29 treated mice was performed. Treatment with [225Ac]Ac-DOTA-4AH29 was repeated in combination with PD-L1 ICB. RESULTS: The biodistribution showed high tumour uptake of [131I]I-GMIB-4AH29 with 3.5 ± 0.5% IA/g 1 h post-injection (p.i.) decreasing to 0.9 ± 0.1% IA/g after 24 h. Tumour uptake of [225Ac]Ac-DOTA-4AH29 was also relevant with 2.1 ± 0.5% IA/g 1 h p.i. with a less steep decrease to 1.7 ± 0.2% IA/g after 24 h. Survival was significantly improved after treatment with low and high doses [131I]I-GMIB-4AH29 or [225Ac]Ac-DOTA-4AH29 compared to vehicle solution. Moreover, we observed significantly higher PD-L1 expression in tumours of mice treated with [225Ac]Ac-DOTA-4AH29 compared to vehicle solution. Therefore, we combined high dose [225Ac]Ac-DOTA-4AH29 with PD-L1 ICB showing therapeutic synergy. CONCLUSION: [225Ac]Ac-DOTA-4AH29 and [131I]I-GMIB-4AH29 exhibit high and persistent tumour targeting, translating into prolonged survival in mice bearing aggressive tumours. Moreover, we demonstrate that the combination of PD-L1 ICB with [225Ac]Ac-DOTA-4AH29 TRT enhances its therapeutic efficacy.
引用
- Ceuppens H, Pombo Antunes AR, Navarro L, et al. Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model. Eur J Nucl Med Mol Imaging. 2024. PMID: 39237746. doi:10.1007/s00259-024-06914-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。